Cargando…
Current Perspectives on HIV-1 Antiretroviral Drug Resistance
Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolu...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213579/ https://www.ncbi.nlm.nih.gov/pubmed/25341668 http://dx.doi.org/10.3390/v6104095 |
_version_ | 1782341845892726784 |
---|---|
author | Iyidogan, Pinar Anderson, Karen S. |
author_facet | Iyidogan, Pinar Anderson, Karen S. |
author_sort | Iyidogan, Pinar |
collection | PubMed |
description | Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly. |
format | Online Article Text |
id | pubmed-4213579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-42135792014-10-31 Current Perspectives on HIV-1 Antiretroviral Drug Resistance Iyidogan, Pinar Anderson, Karen S. Viruses Review Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly. MDPI 2014-10-24 /pmc/articles/PMC4213579/ /pubmed/25341668 http://dx.doi.org/10.3390/v6104095 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Iyidogan, Pinar Anderson, Karen S. Current Perspectives on HIV-1 Antiretroviral Drug Resistance |
title | Current Perspectives on HIV-1 Antiretroviral Drug Resistance |
title_full | Current Perspectives on HIV-1 Antiretroviral Drug Resistance |
title_fullStr | Current Perspectives on HIV-1 Antiretroviral Drug Resistance |
title_full_unstemmed | Current Perspectives on HIV-1 Antiretroviral Drug Resistance |
title_short | Current Perspectives on HIV-1 Antiretroviral Drug Resistance |
title_sort | current perspectives on hiv-1 antiretroviral drug resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213579/ https://www.ncbi.nlm.nih.gov/pubmed/25341668 http://dx.doi.org/10.3390/v6104095 |
work_keys_str_mv | AT iyidoganpinar currentperspectivesonhiv1antiretroviraldrugresistance AT andersonkarens currentperspectivesonhiv1antiretroviraldrugresistance |